BMY · Bristol Myers Squibb Co · Webcasts, Transcripts & Audio
$63.43
+1.11 (+1.78%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$129.66B
Shares
2.04B
Volume · Nov 13
9.27M
Avg daily vol (3M)
10.87M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Bristol Myers Squibb Co Webcasts
Earnings calls, investor updates, investor days and conferences for Bristol Myers Squibb Co (BMY), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-10-29
Bristol Myers Squibb Co (BMY) Q3 2026 Earnings Call Transcript
Confident tone
IPF and PPF development
Growth portfolio performance
Cobenfy commercialization
Revenue
$13.07B
▲ 6.9% YoY Diluted EPS
$1.05
▼ 2.8% YoY Gross margin
68.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-07-30
Bristol Myers Squibb Co (BMY) Q2 2026 Earnings Call Transcript
Confident tone
Pipeline and pivotal readouts
Cobenfy / ADEPT program delays
Milvexian AF study timing
Revenue
$12.97B
▲ 5.7% YoY Diluted EPS
$1.62
▲ 153.1% YoY Gross margin
71.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Bristol Myers Squibb Co (BMY) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-14
Bristol Myers Squibb Co (BMY) May 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-30
Bristol Myers Squibb Co (BMY) Q1 2026 Earnings Call Transcript
Confident tone
Admilperent (LPA1) in IPF and PPF
Growth portfolio performance
Capital allocation, business development, cost savings
Revenue
$11.49B
▲ 2.6% YoY Diluted EPS
$1.31
▲ 9.2% YoY Gross margin
70.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-05
Bristol Myers Squibb Co (BMY) Q4 2025 Earnings Call Transcript
Positive tone
Growth portfolio momentum
Key growth brands
Pipeline catalysts and readouts
Revenue
$12.50B*
▲ 1.3% YoY Gross margin
67.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Bristol Myers Squibb Co (BMY) Q3 2025 Earnings Call Transcript
Confident tone
Cobenfy launch and Alzheimer's psychosis
Growth portfolio performance
Business development and partnerships
Revenue
$12.22B
▲ 2.8% YoY Diluted EPS
$1.08
▲ 80% YoY Gross margin
71.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Bristol Myers Squibb Co (BMY) Q2 2025 Earnings Call Transcript
Positive tone
New product launches
Pipeline catalysts and lifecycle management
Capital deployment and business development
Revenue
$12.27B
▲ 0.6% YoY Diluted EPS
$0.64
▼ 22.9% YoY Gross margin
72.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-24
Bristol Myers Squibb Co (BMY) Q1 2025 Earnings Call Transcript
Positive tone
Business development and capital allocation
Tariffs and policy uncertainty
Growth portfolio and Q1 performance
Revenue
$11.20B
▼ 5.6% YoY Diluted EPS
$1.20
Gross margin
72.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-06
Bristol Myers Squibb Co (BMY) Q4 2024 Earnings Call Transcript
Confident tone
Cobenfy launch and lifecycle
Pipeline catalysts and R&D productivity
Growth portfolio performance
Revenue
$12.34B*
▲ 7.5% YoY Gross margin
61.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Bristol Myers Squibb Co (BMY) Q3 2024 Earnings Call Transcript
Confident tone
Cobenfy launch and schizophrenia opportunity
Milvexian atrial fibrillation trial
Growth portfolio performance
Revenue
$11.89B
▲ 8.4% YoY Diluted EPS
$0.60
▼ 35.5% YoY Gross margin
75.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-26
Bristol Myers Squibb Co (BMY) Q2 2024 Earnings Call Transcript
Confident tone
KarXT Launch Preparation
Policy and IRA Risk
Capital Allocation and Business Development
Revenue
$12.20B
▲ 8.7% YoY Diluted EPS
$0.83
▼ 16.2% YoY Gross margin
73.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-25
Bristol Myers Squibb Co (BMY) Q1 2024 Earnings Call Transcript
Positive tone
Commercial portfolio performance
Inflation Reduction Act (IRA)
Pipeline advancement and cell therapy
Revenue
$11.87B
▲ 4.7% YoY Diluted EPS
$-5.89
▼ 650.5% YoY Gross margin
75.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-02
Bristol Myers Squibb Co (BMY) Q4 2023 Earnings Call Transcript
Positive tone
Commercial performance of growth brands
Eliquis and IRA price negotiations
Financial guidance and margin discipline
Revenue
$11.48B*
▲ 0.6% YoY Gross margin
76.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-26
Bristol Myers Squibb Co (BMY) Q3 2023 Earnings Call Transcript
Revenue
$10.97B
▼ 2.2% YoY Diluted EPS
$0.93
▲ 24% YoY Gross margin
77.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-27
Bristol Myers Squibb Co (BMY) Q2 2023 Earnings Call Transcript
Revenue
$11.23B
▼ 5.6% YoY Diluted EPS
$0.99
▲ 50% YoY Gross margin
74.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-27
Bristol Myers Squibb Co (BMY) Q1 2023 Earnings Call Transcript
Revenue
$11.34B
▼ 2.7% YoY Diluted EPS
$1.07
▲ 81.4% YoY Gross margin
77.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-02
Bristol Myers Squibb Co (BMY) Q4 2022 Earnings Call Transcript
Revenue
$11.41B*
▼ 4.8% YoY Gross margin
77.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-26
Bristol Myers Squibb Co (BMY) Q3 2022 Earnings Call Transcript
Revenue
$11.22B
▼ 3.5% YoY Diluted EPS
$0.75
▲ 8.7% YoY Gross margin
79.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-27
Bristol Myers Squibb Co (BMY) Q2 2022 Earnings Call Transcript
Revenue
$11.89B
▲ 1.6% YoY Diluted EPS
$0.66
▲ 40.4% YoY Gross margin
77.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-29
Bristol Myers Squibb Co (BMY) Q1 2022 Earnings Call Transcript
Revenue
$11.65B
▲ 5.2% YoY Diluted EPS
$0.59
▼ 33.7% YoY Gross margin
78.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-04
Bristol Myers Squibb Co (BMY) Q4 2021 Earnings Call Transcript
Revenue
$11.98B*
▲ 8.3% YoY Gross margin
80.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-27
Bristol Myers Squibb Co (BMY) Q3 2021 Earnings Call Transcript
Revenue
$11.62B
▲ 10.3% YoY Diluted EPS
$0.69
▼ 15.9% YoY Gross margin
80.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-28
Bristol Myers Squibb Co (BMY) Q2 2021 Earnings Call Transcript
Revenue
$11.70B
▲ 15.5% YoY Diluted EPS
$0.47
Gross margin
79.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Bristol Myers Squibb Co (BMY) Q1 2021 Earnings Call Transcript
Revenue
$11.07B
▲ 2.7% YoY Diluted EPS
$0.89
Gross margin
74.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-04
Bristol Myers Squibb Co (BMY) Q4 2020 Earnings Call Transcript
Revenue
$11.07B
▲ 39.3% YoY Diluted EPS
$-4.45
Gross margin
73.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Bristol Myers Squibb Co (BMY) Q3 2020 Earnings Call Transcript
Revenue
$10.54B
▲ 75.5% YoY Diluted EPS
$0.82
▼ 1.2% YoY Gross margin
76.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Bristol Myers Squibb Co (BMY) Q2 2020 Earnings Call Transcript
Revenue
$10.13B
▲ 61.5% YoY Diluted EPS
$-0.04
▼ 104.6% YoY Gross margin
73.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Bristol Myers Squibb Co (BMY) Q1 2020 Earnings Call Transcript
Revenue
$10.78B
▲ 82.1% YoY Diluted EPS
$-0.34
▼ 132.7% YoY Gross margin
66.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-06
Bristol Myers Squibb Co (BMY) Q4 2019 Earnings Call
Revenue
$7.95B
▲ 33% YoY Diluted EPS
$-0.55
▼ 177.5% YoY Gross margin
68.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–30 of 30 webcasts
Key facts
CIK
14272
CUSIP
110122108
13F (30d)
2056 filings
1929 filers
Visit website
Investor relations